By
AmyT on
December 5, 2012
Wow! We’re excited to welcome not one, but three senior FDA officers as joint guest posters here at the ‘Mine today. All three of these individuals attended and participated in the recent 2012 DiabetesMine Innovation Summit, which we hosted at Stanford University on Nov. 16.
Dr. Alberto Gutierrez gave an opening talk titled “How Different Constituencies Can Work Together to Improve Technology Tools for Diabetes Care” (slides here); Stayce Beck participated in our “Data and…
Read more »
By
AmyT on
September 26, 2012
This past Sunday through Tuesday, the legendary Joslin Diabetes Center hosted its first-ever “Diabetes + Innovation” conference at the Crystal City Hyatt hotel in Arlington, VA. (They tell us this DC location was more convenient for the many government and large healthcare orgs participating than Joslin’s home base in Boston.)
As you might imagine, no one could have been more excited than I about the world’s leading diabetes clinic organizing a high-level conference on INNOVATION…
Read more »
Sometimes, diabetes science confuses me.
Let’s take the news of an emerging class of diabetes drugs (type 2-focused) that apparently do something we’ve always thought was bad… but it’s actually not.
Sodium-glucose transporter (SGLT-2) inhibitors increase insulin production and effectiveness and stop the liver from producing too much glucose. Basically, they work by spilling glucose over into the urine which leads to less sugar in your bloodstream. The effect: lower BGs and A1Cs.
Sure, it…
Read more »
By
AmyT on
January 3, 2012
We insulin users have long suspected that the carbohydrate counts on packaged food nutrition labels are not particularly accurate. Who’s with me here?
So in the spirit of turning over a new leaf for a new year, we decided to dig into this a little and find out how nutrition labels are made. Warning: we didn’t much like what we discovered.
Did you know that just like with blood glucose result accuracy, the FDA also…
Read more »
By
AmyT on
December 2, 2011
Yesterday marks “a milestone” in the development of new technology to help automate the care and treatment of type 1 diabetes, according to JDRF!
The U.S. Food and Drug Administration unveiled its eagerly awaited Draft Guidance document for research and development of the Artificial Pancreas system, and initial reaction from JDRF — in a press conference held yesterday afternoon — was a mix of jubilation and a more measured response that they remain “guardedly optimistic” about the details…
Read more »
